Trials / Completed
CompletedNCT00298038
A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Rifaximin 550 mg BID For 6 Months In Preventing Hepatic Encephalopathy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 299 (actual)
- Sponsor
- Bausch Health Americas, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if the study drug is safe and effective in preventing hepatic encephalopathy (HE).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rifaximin | Oral |
| DRUG | Placebo | Oral |
Timeline
- Start date
- 2005-12-19
- Primary completion
- 2008-08-15
- Completion
- 2008-08-15
- First posted
- 2006-03-01
- Last updated
- 2019-09-18
- Results posted
- 2019-08-14
Source: ClinicalTrials.gov record NCT00298038. Inclusion in this directory is not an endorsement.